This is a summary of the European public assessment report (EPAR) for Ibandronic Acid Teva. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Ibandronic Acid Teva.
Therapeutic Indication
### Therapeutic indication **Ibandronic acid 50mg** Ibandronic Acid Teva is indicated for the prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases. **Ibandronic acid 150mg** Treatment of osteoporosis in postmenopausal women at increased risk of fracture. A reduction in the risk of vertebral fractures has been demonstrated, efficacy on femoral neck fractures has not been established.
Therapeutic Area (MeSH)
ATC Code
M05BA06
ATC Item
ibandronic acid
Pharmacotherapeutic Group
Drugs for treatment of bone diseases
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| ibandronic acid | N/A | 伊班膦酸钠 |
EMA Name
Ibandronic Acid Teva
Medicine Name
Ibandronic Acid Teva
Aliases
N/ANo risk management plan link.
